| Revenue growth | 2% YoY in Q4; 3% YoY for FY26. |
|---|---|
| Margins | Operating EBITDA margin compressed to 25% for FY26 from 29% in FY25. |
| Demand visibility | Strong; ~400 active clients, 16 of top 20 pharma companies. |
| Management confidence | High; expanding leadership team and multi-modal facilities. |
Growth
Q4 FY26 Revenue grew 2% YoY; PAT before exceptional items fell 16% YoY. Full year FY26 Revenue grew 3% YoY.
Outlook
Investments in peptides, ADCs, and Biologics; infrastructure expansion in Bangalore, Hyderabad, and Baltimore site acquisition.
Risks
PAT decline due to lower margins (29% vs 34% in Q4 FY25) and foreign exchange volatility.
Earnings Call filed with BSE, NSE: SYNGENE. Summary written with AI assistance from the document.
Syngene International Ltd: key numbers
- Share price
- ₹378.70
- Market cap
- ₹15,287 Cr
- Revenue (annual)
- ₹3,739 Cr
- Net profit (annual)
- ₹316.7 Cr
- P/E (TTM)
- 69.2×Sector 50.4×
- Promoter holding
- 52.59%-0.09% QoQ
- FII holding
- 11.82%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Syngene International Ltd
All →Syngene International Management Change
Syngene International Limited announced the resignation of Mr. Pramuch Goel, Head of Corporate Affairs & Communications and Senior Management Personnel, effective September 21, 2026.
Syngene International Other Announcement
Syngene International Limited has issued a communication to shareholders regarding the remittance of the final dividend for the financial year 2025-26.
Syngene International Investor Presentation: Key Takeaways
Syngene reports Q1 FY27 revenue of Rs 736 Cr (-16% YoY). Performance was impacted by low offtake from a major client and forex losses.
Syngene International Q1 FY27 Results: Net Loss of ₹9 Cr
Syngene International Ltd reported revenue from operations of ₹736 Cr (-15.8% YoY) and a net loss of ₹9 Cr for Q1 FY27.
- Key figure
- Net loss ₹9 Cr
Syngene International Earnings Call: Key Takeaways
Syngene FY26 results show muted 3% revenue growth due to 'Librela' destocking headwinds. Management indicates FY27 will be a transition year with flat revenue and mid-20s EBITDA margins.
Syngene International Earnings Call: Key Takeaways
Syngene faces a transition year in FY27 as the Librela de-stocking headwind masks underlying momentum in biologics and research services.